mv4 Search Results


mv4 11  (ATCC)
99
ATCC mv4 11
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4 11, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4 11/product/ATCC
Average 99 stars, based on 1 article reviews
mv4 11 - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier
mv4 11  (CLS Cell Lines Service GmbH)
94
CLS Cell Lines Service GmbH mv4 11
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4 11, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4 11/product/CLS Cell Lines Service GmbH
Average 94 stars, based on 1 article reviews
mv4 11 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
colo-205  (Biochrom)
90
Biochrom colo-205
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Colo 205, supplied by Biochrom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/colo-205/product/Biochrom
Average 90 stars, based on 1 article reviews
colo-205 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mv4-11 cells  (Promega)
90
Promega mv4-11 cells
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4 11 Cells, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4-11 cells/product/Promega
Average 90 stars, based on 1 article reviews
mv4-11 cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
dna isolated from mv4-11, molm-13, pl-21, and eol-1 cell lines with known flt3 itds  (SeraCare Life Sciences)
90
SeraCare Life Sciences dna isolated from mv4-11, molm-13, pl-21, and eol-1 cell lines with known flt3 itds
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Dna Isolated From Mv4 11, Molm 13, Pl 21, And Eol 1 Cell Lines With Known Flt3 Itds, supplied by SeraCare Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna isolated from mv4-11, molm-13, pl-21, and eol-1 cell lines with known flt3 itds/product/SeraCare Life Sciences
Average 90 stars, based on 1 article reviews
dna isolated from mv4-11, molm-13, pl-21, and eol-1 cell lines with known flt3 itds - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
subcutaneous mv4-11 xenograft model  (Piedmont Research Center)
90
Piedmont Research Center subcutaneous mv4-11 xenograft model
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Subcutaneous Mv4 11 Xenograft Model, supplied by Piedmont Research Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/subcutaneous mv4-11 xenograft model/product/Piedmont Research Center
Average 90 stars, based on 1 article reviews
subcutaneous mv4-11 xenograft model - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mv4-11  (LGC Promochem)
90
LGC Promochem mv4-11
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4 11, supplied by LGC Promochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4-11/product/LGC Promochem
Average 90 stars, based on 1 article reviews
mv4-11 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cell line xenografts mv-4-11  (AstraZeneca ltd)
90
AstraZeneca ltd cell line xenografts mv-4-11
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Cell Line Xenografts Mv 4 11, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell line xenografts mv-4-11/product/AstraZeneca ltd
Average 90 stars, based on 1 article reviews
cell line xenografts mv-4-11 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
lactobacillus delbrueckii phage mv4  (DuPont de Nemours)
90
DuPont de Nemours lactobacillus delbrueckii phage mv4
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Lactobacillus Delbrueckii Phage Mv4, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lactobacillus delbrueckii phage mv4/product/DuPont de Nemours
Average 90 stars, based on 1 article reviews
lactobacillus delbrueckii phage mv4 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
lactobacillus delbrueckii subsp. bulgaricus bacteriophage mv4  (DuPont de Nemours)
90
DuPont de Nemours lactobacillus delbrueckii subsp. bulgaricus bacteriophage mv4
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Lactobacillus Delbrueckii Subsp. Bulgaricus Bacteriophage Mv4, supplied by DuPont de Nemours, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lactobacillus delbrueckii subsp. bulgaricus bacteriophage mv4/product/DuPont de Nemours
Average 90 stars, based on 1 article reviews
lactobacillus delbrueckii subsp. bulgaricus bacteriophage mv4 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mv4-11 cells  (Cyagen Biosciences)
90
Cyagen Biosciences mv4-11 cells
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4 11 Cells, supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4-11 cells/product/Cyagen Biosciences
Average 90 stars, based on 1 article reviews
mv4-11 cells - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
mv4;11 xenografts  (MultiCell Technologies)
90
MultiCell Technologies mv4;11 xenografts
FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT <t>mutation),</t> <t>MV4–11</t> (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.
Mv4;11 Xenografts, supplied by MultiCell Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mv4;11 xenografts/product/MultiCell Technologies
Average 90 stars, based on 1 article reviews
mv4;11 xenografts - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT mutation), MV4–11 (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.

Journal: RNA nanomed

Article Title: CD133-Guided RNA Nanoparticle Delivery of FTO siRNA Impairs Leukemia Resistance to Tyrosine Kinase Inhibitor Therapy

doi: 10.59566/isrnn.2025.0201e

Figure Lengend Snippet: FTO inhibitors induce the upregulation of FTO protein expression. Leukemia cells Kasumi-1 (AML, with AML1/ETO translocation and an activating KIT mutation), SKNO-1 (AML, with AML1/ETO translocation and an activating KIT mutation), MV4–11 (AML, with AF-4/FEL translocation and activating FLT3 mutation) and K562 (CML, with BCR/ABL translocation and activating ABL kinase) were treated with FB23-2 (10 μM), CS1 (1 μM) or CS2 (1 μM) for 48 hours. The FTO protein expression was determined by Western blot. Data are representative of three independent experiments. NIR, nilotinib resistance; IMA: Imatinib resistance; Con, Control.

Article Snippet: Leukemia cell lines, K562, MV4–11 and Kasumi-1, were newly purchased from American Type Culture Collection with no further authentication or testing for mycoplasma.

Techniques: Expressing, Translocation Assay, Mutagenesis, Western Blot, Control

Expression and regulation of LSC markers in naïve, larger clones and TKI resistant leukemia cells. (A) Quantification of CD25+ cells in K562 cells treated with 0.3 or 1 μM of nilotinib for 48 hours, as measured by flow cytometry. (B) Left: Graphs representing colony numbers of parental and nilotinib-resistant K562 cells cultured in drug-free medium for 72 hours; Right: Flow cytometry analysis depicting the percentage of CD25+ cells in large vs small clones. (C) Graphs showing quantification of CD25+, CD44+ and CD133+ cells measured in parental vs NIR or IMR K562 cells, as measured by flow cytometry. (D) qPCR measuring indicated LSC marker expression in parental vs resistant Kasumi-1, MV4–11 and K562 cells. (E) Western blot and quantification of KIT (CD117) and EZH2 protein expression in parental, NIR-resistant, and IMR-resistant K562 cells. Band intensity was quantified and normalized to a loading control (β-actin). (F-G) qPCR measuring changes in the indicated stem cell markers in FTO knockdown (F) or FTO inhibitor CS2-treated (G) K562 cells resistant to nilotinib. (H) m 6 A immunoprecipitation (IP) was performed in mRNA from K562 resistant cells. The eluted RNA was converted to cDNA and transcript levels of KIT, CD25 and CD44 were measured by qPCR. Data are representative of three independent experiments. Par, parental; NIR, nilotinib resistance; IMR, imatinib resistance; Kas, Kasumi-1; shctrl, scramble control; * P <0.05, ** P <0.01, *** P <0.001; ns, not statistically significant.

Journal: RNA nanomed

Article Title: CD133-Guided RNA Nanoparticle Delivery of FTO siRNA Impairs Leukemia Resistance to Tyrosine Kinase Inhibitor Therapy

doi: 10.59566/isrnn.2025.0201e

Figure Lengend Snippet: Expression and regulation of LSC markers in naïve, larger clones and TKI resistant leukemia cells. (A) Quantification of CD25+ cells in K562 cells treated with 0.3 or 1 μM of nilotinib for 48 hours, as measured by flow cytometry. (B) Left: Graphs representing colony numbers of parental and nilotinib-resistant K562 cells cultured in drug-free medium for 72 hours; Right: Flow cytometry analysis depicting the percentage of CD25+ cells in large vs small clones. (C) Graphs showing quantification of CD25+, CD44+ and CD133+ cells measured in parental vs NIR or IMR K562 cells, as measured by flow cytometry. (D) qPCR measuring indicated LSC marker expression in parental vs resistant Kasumi-1, MV4–11 and K562 cells. (E) Western blot and quantification of KIT (CD117) and EZH2 protein expression in parental, NIR-resistant, and IMR-resistant K562 cells. Band intensity was quantified and normalized to a loading control (β-actin). (F-G) qPCR measuring changes in the indicated stem cell markers in FTO knockdown (F) or FTO inhibitor CS2-treated (G) K562 cells resistant to nilotinib. (H) m 6 A immunoprecipitation (IP) was performed in mRNA from K562 resistant cells. The eluted RNA was converted to cDNA and transcript levels of KIT, CD25 and CD44 were measured by qPCR. Data are representative of three independent experiments. Par, parental; NIR, nilotinib resistance; IMR, imatinib resistance; Kas, Kasumi-1; shctrl, scramble control; * P <0.05, ** P <0.01, *** P <0.001; ns, not statistically significant.

Article Snippet: Leukemia cell lines, K562, MV4–11 and Kasumi-1, were newly purchased from American Type Culture Collection with no further authentication or testing for mycoplasma.

Techniques: Expressing, Clone Assay, Flow Cytometry, Cell Culture, Marker, Western Blot, Control, Knockdown, Immunoprecipitation